REGENXBIO Inc. (RGNX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by REGENXBIO Inc. on January 23, 2026, reporting an event that occurred on January 28, 2026. The Company is a biopharmaceutical firm focused on developing gene therapies, with its principal executive offices located in Rockville, Maryland.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the placement of clinical holds by the U.S. Food and Drug Administration (FDA) on two of the Company's Investigational New Drug (IND) applications:
- RGX-111: Phase I/II trial for Mucopolysaccharidosis type I.
- RGX-121: Phase I/II/III trial for Mucopolysaccharidosis type II.
Outlook, Risks, and Management Commentary
The clinical hold represents a significant regulatory risk and contingency that halts the advancement of these specific drug candidates. The filing incorporates a press release (Exhibit 99.1) detailing the FDA communication but does not include specific management commentary on the timeline for resolution, the specific reasons for the hold, or revised financial guidance within the text of this 8-K.
Key Facts for Investor Verification
- Verify the specific reasons cited by the FDA for the clinical holds on RGX-111 and RGX-121 in the attached press release (Exhibit 99.1).
- Confirm the expected timeline for resolving the clinical holds and resuming trials.
- Assess the impact of these holds on the Company's overall pipeline and potential future revenue streams.
- Review recent financial filings (10-K or 10-Q) for current cash runway, as this 8-K does not disclose liquidity status.